文献速递妇科肿瘤

中国宫颈癌筛查中高危型HPV检测有效性的多中心随机试验

Effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in China: A Multicenter, Open-label, Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2021-01-01

结果显示hrHPV检测作为初筛可显著提高CIN2+和CIN3+检出,且24个月后阴性者风险显著低于细胞学或VIA/VILI。细胞学分流可降低阴道镜转诊率,将hrHPV检测纳入国家筛查规划合理。

要点

  • hrHPV初筛的CIN2+和CIN3+检出风险比显著高于细胞学或VIA/VILI。
  • hrHPV初筛阴性者24个月CIN2+和CIN3+风险显著低于细胞学或VIA/VILI。
  • 细胞学分流可降低hrHPV阳性者的阴道镜转诊率并维持较高检出。

核心结论

  • 在基层卫生中心,hrHPV检测是有效的初筛方法,将其纳入中国国家筛查规划合理。

主要发现

  • 城市hrHPV直接阴道镜组基线CIN2+风险比为2.2(95%CI 1.6-3.2),CIN3+为2.0(95%CI 1.2-3.3),对照为细胞学。
  • 农村hrHPV直接阴道镜组基线CIN2+风险比为2.6(95%CI 1.9-4.0),CIN3+为2.7(95%CI 2.0-3.6),对照为细胞学。
  • 农村hrHPV直接阴道镜组基线CIN2+风险比为2.0(95%CI 1.6-2.3),CIN3+为2.3(95%CI 1.8-3.1),对照为VIA/VILI。
  • 24个月时农村hrHPV初筛阴性者CIN2+风险比为0.3(95%CI 0.2-0.5)对细胞学、0.3(95%CI 0.2-0.6)对VIA/VILI,CIN3+为0.3(95%CI 0.1-0.6)和0.4(95%CI 0.2-0.8)。
  • 农村hrHPV阳性细胞学分流后阴道镜转诊率降至2.8%,CIN2+检出风险比2.1(95%CI 1.3-2.6)对细胞学、1.6(95%CI 1.03-2.1)对VIA/VILI。

临床怎么用

  • 城市地区可考虑采用基于PCR的hrHPV检测作为初筛,农村地区可考虑基于杂交捕获的hrHPV检测。
  • hrHPV阳性者可结合细胞学分流以降低阴道镜转诊率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Evidence is needed regarding the introduction of high-risk human papillomavirus (hrHPV) testing into China's national cervical cancer screening program. OBJECTIVE: To evaluate hrHPV testing as a new screening modality for the national program. DESIGN, SETTING, AND PARTICIPANTS: This population-based, multicenter, open-label, randomized clinical trial took place across 20 primary health care centers in urban and rural areas across China. At least 3000 women aged 35 to 64 years per site were invited to participate, for a total of 60 732 women evaluated. INTERVENTIONS: At baseline, women were randomly assigned to cytology, hrHPV testing, or visual inspection with acetic acid and Lugol iodine (VIA/VILI) (rural only). Women who tested positive for hrHPV were randomized into cytology-triage, VIA/VILI-triage (rural only), or direct colposcopy arms. Regarding primary or triaging tests, women with cytological abnormalities or who tested positive with VIA/VILI were referred to colposcopy. After 24 months, combined screening of cytology, hrHPV testing, and VIA/VILI was performed, and all women with positive results were referred to colposcopy. MAIN OUTCOMES AND MEASURES: The primary outcomes were cervical intraepithelial neoplasia grade 2 or worse (CIN2+) and CIN3+ yields. The secondary outcome was colposcopy referral rate. RESULTS: A total of 60 732 women were included in this study, with median (interquartile range) age of 47 (41-52) years. Among urban women, 8955 were randomized to cytology and 18 176 to hrHPV genotyping; among rural women, 11 136 were randomized to VIA/VILI, 7080 to cytology, and 15 385 to hrHPV testing. Participants who tested positive for hrHPV with direct colposcopy had higher risk ratios for disease yields at baseline (urban hrHPV vs cytology, CIN2+ 2.2 [95% CI, 1.6-3.2] and CIN3+ 2.0 [95% CI, 1.2-3.3]; rural hrHPV vs cytology, 2.6 [95% CI, 1.9-4.0] and 2.7 [95% CI, 2.0-3.6]; rural hrHPV vs VIA/VILI, 2.0 [95% CI, 1.6-2.3] and 2.3 [95% CI, 1.8-3.1]). At 24 months, baseline-negative women in the hrHPV arm had significantly lower risk ratios than those with cytology, or VIA/VILI for CIN2+ (0.3 [95% CI, 0.2-0.5], 0.3 [95% CI, 0.2-0.6]) and CIN3+ (0.3 [95% CI, 0.1-0.6], 0.4 [95% CI, 0.2-0.8]) in rural sites. The colposcopy referral rate for hrHPV-positive rural women was reduced to 2.8% by cytology triage, with significantly higher CIN2+ yields than cytology (2.1 [95% CI, 1.3-2.6]) or VIA/VILI arm (1.6 [95% CI, 1.03-2.1]). Genotyping for hrHPV with cytology triage significantly reduced the colposcopy referral rate compared with cytology (0.8 [95% CI, 0.7-0.9]) for urban women. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, testing for hrHPV was an effective primary screening method in primary health care centers. Incorporating hrHPV testing (polymerase chain reaction-based for urban areas, hybrid capture-based for rural areas) into China's national screening program is reasonable. TRIAL REGISTRATION: Chinese Clinical Trial Registry Identifier: ChiCTR1900022530.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Zhang J, Zhao Y, Dai Y, et al. Effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in China: A Multicenter, Open-label, Randomized Clinical Trial. JAMA Oncol. 2021. PMID: 33377903. doi:10.1001/jamaoncol.2020.6575

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。